Literature DB >> 11327825

Antibody 17b binding at the coreceptor site weakens the kinetics of the interaction of envelope glycoprotein gp120 with CD4.

W Zhang1, A P Godillot, R Wyatt, J Sodroski, I Chaiken.   

Abstract

HIV-1 utilizes CD4 and the chemokine coreceptor for viral entry. The coreceptor CCR5 binding site on gp120 partially overlaps with the binding epitope of 17b, a neutralizing antibody of HIV-1. We designed a multicomponent biosensor assay to investigate the kinetic mechanism of interaction between gp120 and its receptors and the cooperative effect of the CCR5 binding site on the CD4 binding site, using 17b as a surrogate of CCR5. The Env gp120 proteins from four viral strains (JRFL, YU2, 89.6, and HXB2) and their corresponding C1-, V1/V2-, C5-deleted mutants (DeltaJRFL, DeltaYU2, Delta89.6, and DeltaHXB2) were tested in this study. We found that, across the primary and lab-adapted virus strains, 17b reduced the affinity of all four full-length Env gp120s for sCD4 by decreasing the on-rate and increasing the off-rate. This effect of 17b on full-length gp120 binding to sCD4 contrasts with the enhancing effect of sCD4 on gp120-17b interaction. For the corresponding loop-deleted mutants of Env gp120, the off-rates of the gp120-sCD4 interaction were greatly reduced in the presence of 17b, resulting in higher affinities (except for that of DeltaHXB2). The results suggest that, when 17b is prebound to full-length gp120, the V1/V2 loops may be relocated to a position that partially blocks the CD4-binding site, leading to weakening of the CD4 interaction. Given the fact that the 17b binding epitope partially overlaps with the binding site of CCR5, the kinetic results suggest that coreceptor CCR5 binding could have a similar "release" effect on the gp120-CD4 interaction by increasing the off-rate of the latter. The results also suggest that the neutralizing effect of 17b may arise not only from partially blocking the CCR5 binding site but also from reducing the CD4 binding affinity of gp120. This negative cooperative effect of 17b may provide insight into approaches to designing antagonists for viral entry.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11327825     DOI: 10.1021/bi001397m

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  33 in total

1.  Restraining the conformation of HIV-1 gp120 by removing a flexible loop.

Authors:  Sophia Rits-Volloch; Gary Frey; Stephen C Harrison; Bing Chen
Journal:  EMBO J       Date:  2006-09-28       Impact factor: 11.598

2.  Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein.

Authors:  Feng Gao; Eric A Weaver; Zhongjing Lu; Yingying Li; Hua-Xin Liao; Benjiang Ma; S Munir Alam; Richard M Scearce; Laura L Sutherland; Jae-Sung Yu; Julie M Decker; George M Shaw; David C Montefiori; Bette T Korber; Beatrice H Hahn; Barton F Haynes
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

3.  Global shape and ligand binding efficiency of the HIV-1-neutralizing antibodies differ from those of antibodies that cannot neutralize HIV-1.

Authors:  Ashish K Solanki; Yogendra S Rathore; Maulik D Badmalia; Reema R Dhoke; Samir K Nath; Deepak Nihalani
Journal:  J Biol Chem       Date:  2014-10-20       Impact factor: 5.157

4.  Flow virometric sorting and analysis of HIV quasispecies from plasma.

Authors:  Thomas Musich; Jennifer C Jones; Brandon F Keele; Lisa M Miller Jenkins; Thorsten Demberg; Thomas S Uldrick; Robert Yarchoan; Marjorie Robert-Guroff
Journal:  JCI Insight       Date:  2017-02-23

5.  Concordant modulation of neutralization resistance and high infectivity of the primary human immunodeficiency virus type 1 MN strain and definition of a potential gp41 binding site in gp120.

Authors:  Maria Leavitt; Eun Ju Park; Igor A Sidorov; Dimiter S Dimitrov; Gerald V Quinnan
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

6.  PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4.

Authors:  Emilia Falkowska; Alejandra Ramos; Yu Feng; Tongqing Zhou; Stephanie Moquin; Laura M Walker; Xueling Wu; Michael S Seaman; Terri Wrin; Peter D Kwong; Richard T Wyatt; John R Mascola; Pascal Poignard; Dennis R Burton
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

7.  Characterization of gp120 and its single-chain derivatives, gp120-CD4D12 and gp120-M9: implications for targeting the CD4i epitope in human immunodeficiency virus vaccine design.

Authors:  Raghavan Varadarajan; Deepak Sharma; Kausik Chakraborty; Mayuri Patel; Michael Citron; Prem Sinha; Ramkishor Yadav; Umar Rashid; Sarah Kennedy; Debra Eckert; Romas Geleziunas; David Bramhill; William Schleif; Xiaoping Liang; John Shiver
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

8.  The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes.

Authors:  S Munir Alam; Mildred McAdams; David Boren; Michael Rak; Richard M Scearce; Feng Gao; Zenaido T Camacho; Daniel Gewirth; Garnett Kelsoe; Pojen Chen; Barton F Haynes
Journal:  J Immunol       Date:  2007-04-01       Impact factor: 5.422

9.  HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition.

Authors:  Heather A Prentice; Georgia D Tomaras; Daniel E Geraghty; Richard Apps; Youyi Fong; Philip K Ehrenberg; Morgane Rolland; Gustavo H Kijak; Shelly J Krebs; Wyatt Nelson; Allan DeCamp; Xiaoying Shen; Nicole L Yates; Susan Zolla-Pazner; Sorachai Nitayaphan; Supachai Rerks-Ngarm; Jaranit Kaewkungwal; Punnee Pitisuttithum; Guido Ferrari; M Juliana McElrath; David C Montefiori; Robert T Bailer; Richard A Koup; Robert J O'Connell; Merlin L Robb; Nelson L Michael; Peter B Gilbert; Jerome H Kim; Rasmi Thomas
Journal:  Sci Transl Med       Date:  2015-07-15       Impact factor: 17.956

10.  Biochemical and genetic characterizations of a novel human immunodeficiency virus type 1 inhibitor that blocks gp120-CD4 interactions.

Authors:  Qi Guo; Hsu-Tso Ho; Ira Dicker; Li Fan; Nannan Zhou; Jacques Friborg; Tao Wang; Brian V McAuliffe; Hwei-Gene Heidi Wang; Ronald E Rose; Hua Fang; Helen T Scarnati; David R Langley; Nicholas A Meanwell; Ralph Abraham; Richard J Colonno; Pin-Fang Lin
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.